4D Molecular Therapeutics (FDMT) Accumulated Expenses (2019 - 2026)
4D Molecular Therapeutics (FDMT) posted quarterly Accumulated Expenses of $6.2 million for Q1 2026, up 10.38% year-over-year from $5.7 million in Q1 2025, and down 54.77% quarter-over-quarter from $13.8 million in Q4 2025.
4D Molecular Therapeutics (FDMT) Accumulated Expenses (2019 - 2026) Analysis & Trends
4D Molecular Therapeutics (FDMT) has reported Accumulated Expenses for 8 consecutive years, with $6.2 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Accumulated Expenses rose 10.38% year-over-year to $6.2 million; the TTM figure through Mar 2026 stood at $6.2 million (up 10.38% YoY), while the FY2025 annual figure was $13.8 million, down 26.83% from the prior year.
- Accumulated Expenses declined to $6.2 million in Q1 2026 per FDMT's latest filing, from $13.8 million in the prior quarter.
- Across five years, Accumulated Expenses topped out at $24.2 million in Q3 2025 and bottomed at $2.9 million in Q2 2022.
- Historically, Accumulated Expenses has averaged $9.2 million across 5 years, with a median of $6.2 million in 2026.
- Annual changes were most pronounced in 2022 — Accumulated Expenses slumped 40.04% — and 2025, when it jumped 249.29%.
- 4D Molecular Therapeutics' Accumulated Expenses stood at $5.7 million in 2022, then soared by 43.24% to $8.1 million in 2023, then soared by 131.55% to $18.9 million in 2024, then declined by 26.83% to $13.8 million in 2025, then plunged by 54.77% to $6.2 million in 2026.
- Business Quant data shows FDMT's Accumulated Expenses at $6.2 million in Q1 2026, $13.8 million in Q4 2025, and $24.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | 4D Molecular Therapeutics | 856.62 Mn | 495.28 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 25.43 Mn |
| Mar 31, 2026 | 6.24 Mn |
| Dec 31, 2025 | 13.81 Mn |
| Sep 30, 2025 | 24.19 Mn |
| Jun 30, 2025 | 19.19 Mn |
| Mar 31, 2025 | 5.66 Mn |
| Dec 31, 2024 | 18.87 Mn |
| Sep 30, 2024 | 9.61 Mn |
| Jun 30, 2024 | 5.49 Mn |
| Mar 31, 2024 | 4.52 Mn |
| Dec 31, 2023 | 8.15 Mn |
| Sep 30, 2023 | 10.19 Mn |
| Jun 30, 2023 | 3.96 Mn |
| Mar 31, 2023 | 5.41 Mn |
| Dec 31, 2022 | 5.69 Mn |
| Sep 30, 2022 | 7.24 Mn |
| Jun 30, 2022 | 2.93 Mn |
| Mar 31, 2022 | 5.26 Mn |
| Dec 31, 2021 | 3.99 Mn |
| Sep 30, 2021 | 3.68 Mn |